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Abstract 
Background 
Clinical trials oversight by a Trial Steering Committee (TSC) is mandated by Good Clinical Practice. 
This study used qualitative methods to explore the role and valued attributes of the TSC to inform 
planned updates of Medical Research Council guidance and TSC terms of reference. 
Methods 
An ethnographic study design was conducted during 2013-2014. TSC and Trial Management Group 
meetings from eight trials were observed and audio-recorded, and semi-structured interviews 
conducted with purposively sampled key informants: independent and non-independent TSC 
members, trial sponsor representatives, funder representatives and chief investigators. The selected 
trials were currently recruiting and dealing with challenging scenarios. Data were analysed 
thematically and findings triangulated and integrated to give a multi-perspective account of the role 
and valued attributes of a TSC.   
Results 
Eight TSC meetings and six Trial Management Group meetings were observed. 65 interviews were 
conducted with 51 informants. The two main roles played by the TSC were quality assurance and 
patient advocacy. Quality assurance involved being a ‘critical friend’ or provider of ‘tough love’. 
Factors influencing the ability of the TSC to fulfil this role included the TSC Chair, other independent 
TSC members, and the model of the TSC and its fit with the trial subject. The role of the TSC as an 
advocate for patient well-being was perceived as paramount. Two attributes of TSC members 
emerged as critical: experience (of running a trial, trial oversight or in a clinical/methodological area) 
and independence. While independence was valued for giving impartiality, the lack of consensus 
about its definition and strict requirements of some funders made it difficult to operationalise.          
Conclusions 
We found tensions and ambiguities in the roles expected of TSCs and the attributes valued of TSC 
members. In particular, the requirements of independence and experience could conflict, impacting 
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on TSCs’ quality assurance role. Concerns were raised regarding whose interests are served by 
funders’ criteria of independence; in particular, funders’ selection of TSC members was thought to 
potentially inhibit TSCs’ ability to fulfil their patient advocacy role. These findings should be 
incorporated in revising guidance and terms of reference for TSCs. 
Keywords 
Randomised trials, Good Clinical Practice, Terms of Reference, Trial Steering Committees, Trial 
Monitoring   
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Background 
Good oversight of late-phase randomised controlled trials (RCTs) is part of the quality assurance 
process. While there is acknowledged variation in oversight practice within the UK and 
internationally [1], the UK Medical Research Council (MRC) Guidelines for Good Clinical Practice 
(1998) recommend that trial oversight should include an element of expert advice that is 
independent of the Chief Investigator (CI) and host institution involved [2]. This oversight is usually 
provided by a Trial Steering Committee (TSC).  
In the tripartite trial oversight structure recommended by the MRC, the role of the TSC is to act as an 
executive body providing overall supervision of the trial [2]. The TSC considers the recommendations 
made by the Data Monitoring Committee (DMC), which reviews safety and efficacy data, and steers 
the Trial Management Group (TMG) responsible for the day-to-day delivery and conduct of the trial. 
TSCs are expected to monitor and supervise the progress of the trial, review information from other 
sources (such as related trials), communicate the progress of the trial to relevant parties (such as 
sponsors and funders), and advise on publicity and presentation of all aspects of the trial [2]. The 
inclusion in TSCs of members who are independent of both the trial and its TMG is seen as critical in 
avoiding real or perceived conflict of interest or bias [3] and protecting both trial participants and CIs 
[4]. The MRC recommends that membership of a TSC should include the CI, who is regarded as being 
non-independent of the trial, an independent Chair and no fewer than two other independent 
members [2]. Whilst non-independent members of the trial team can attend TSC meetings, their role 
is solely to provide information and clarification to independent TSC members. 
However, there are apparent inconsistencies or ambiguities in some of the guidance related to TSCs. 
According to the MRC’s Guidelines for Good Clinical Practice, for example, the TSC prioritises the 
rights, safety and well-being of the trial participants over the interests of science and society [2], yet 
its more recent guidance specifies that trial supervision by the TSC is “on behalf of the Trial Sponsor 
and Trial Funder” [4]. Definitions of ‘independence’ as it applies to trial oversight also vary. These 
include “not involved directly in the trial other than as a member of the TSC” [1], “independent of 
the investigators, their employing organisations, funders and sponsors” [4], and having no stock 
ownership in any pharmaceutical company involved, no frequent speaking engagements on behalf 
of the intervention, no emotional involvement in the running of the trial and not being employed in 
the same workplace as major members of the trial team [3]. 
Previous qualitative research in the DAMOCLES project examined the role of DMCs in overseeing 
trial data collection procedures and advising TSCs [5], resulting in the now widely-used 2005 charter 
for DMCs [6, 7]. However, little attention has been given to the role and function of TSCs and how 
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guidance on TSCs such as that produced by the MRC is applied within trial oversight [7]. Two recent 
studies have begun to consider these questions [1, 7, 8]. A quantitative survey of 38 UK clinical trials 
units [7] found that greater clarity is needed regarding the relationship between a TSC and the trial 
funder or sponsor and the extent of independence required from TSC members. Similarly, Harman et 
al’s report of an expert panel review on the role and function of TSCs suggests that the nature of 
TSCs’ independence, the manner in which TSC members should be appointed and to whom a TSC is 
responsible are unclear [8]. These study designs, however, did not allow in-depth exploration of the 
role of TSCs in practice. To complement these studies and inform future revisions of MRC guidance 
and TSC terms of reference, we aimed to explore the role and valued attributes of TSCs using a 
multi-perspective ethnographic design.  
Methods  
A cross-sectional ethnographic study was conducted, using non-participant observation and 
interviews to explore the role and value of TSCs. Findings from observation of TSC and TMG 
meetings were triangulated and integrated with findings from interviews with independent and non-
independent TSC members, trial sponsors, funders and CIs to give a rich, multi-perspective account. 
Our research is situated within a post-positivist, minimally realist paradigm appropriate to applied 
health services research [9].   
Sample and setting  
Based on the research team’s experience and expertise in trials, we hypothesised that the role and 
value of TSCs would be more clearly articulated in TSCs dealing with challenging scenarios than in 
other trials. We therefore included trials if they were currently experiencing a difficulty, e.g. 
recruitment issues, protocol amendments or deviations, participating centres experiencing 
problems, early release of safety data, early publishing of data, and recommendations from DMC to 
stop recruitment. A second inclusion criterion was having a TSC meeting planned within the study 
period (March 2013 – January 2014).  
Eight randomised trials meeting the criteria were purposively selected to represent a range of 
clinical topics (e.g. elderly care, cancer, mental health), healthcare settings (primary and secondary 
care), interventions (e.g. pharmaceutical and  psychological), and oversight committee structures 
(e.g. dedicated TSC serving one trial or ‘umbrella’ TSC overseeing several trials). The sample size of 
eight was chosen to enable in-depth fieldwork and analysis across a diverse range of trials. Trials 
were identified through the UKCRC Registered Clinical Trials Unit Network [10] and a major UK 
funder of trials. The CTU Network nominated trials and approached trial Chief Investigators (CIs) to 
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invite inclusion of their trial. In addition, the funder identified trials facing difficulties and contacted 
the CIs with invitations to participate. CIs interested in their trial participating contacted the 
research team directly.  
Purposive sampling was used to select independent and non-independent TSC members with 
differing perspectives on and involvement in the selected trials. Independent TSC members included 
TSC Chairs and non-independent members included TMG members. Data collection continued for 
each trial until data saturation was reached, i.e. no new themes emerged during data analysis [11]. 
Supplementary interviews were conducted with representatives of a purposive selection of trial 
funders, sponsors, and CIs with experience of other challenging trials to gain wider perspectives. 
Data collection 
All observational and interview data was collected by the same researcher (AD), a qualitative 
researcher experienced in health services research. 
Observational data  
One TSC meeting was attended, observed and audio-recorded for each trial, with prior consent from 
TSC members. In addition, to provide a context for discussions within TSC meetings the researcher 
attended, observed and audio-recorded relevant TMG meetings during the study period. Detailed 
field notes were taken during and after the meetings, guided by a standardised observation 
schedule.  
Interviews 
TSC members were invited for interview by the relevant trial CI or by the researcher approaching 
them directly at meetings. Interviews were conducted before or after the TSC meeting depending on 
participant availability and preference. Supplementary interviews were conducted with funder, 
sponsor and CI representatives known to have differing opinions regarding the role and value of 
TSCs, identified via snowball sampling [12]. All interviews were either face-to-face or by telephone, 
depending on participant preference, and were recorded and transcribed verbatim.  
The semi-structured interview topics guides formulated on the basis of the literature regarding trial 
oversight and the research team’s expertise are summarised in Box 1.  
Box 1: Interview topic guides 
Participant group Topics discussed in interviews 
Chief Investigator  The trial: History of the trial, details of the trial, current stage, successes, current and 
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TSC Chair  anticipated challenges   
The TSC: Frequency of meetings, composition of TSC, reasons for selecting members, how 
Chair was selected and role in meetings, nature of the group’s decision-making and 
members’ involvement, examples of actioned group recommendations, impact of TSC, 
communication between TSC and TMG, relationship of and communication between TSC 
and other trial oversight committees, aspects of TSC that could be improved, 
recommendations for other trials regarding role of TSC 
TSC members  The trial: History of participation in the TSC, views regarding composition of the group and 
frequency of meetings, relationships with other members, value of TSC meetings, TSC’s 
role in decisions regarding trial, relationship of and communication between TSC, TMG 
and other trial oversight committees 
TSC meetings: Meeting organisation, Chair and leadership of meeting, communication 
during meeting, process of decision-making (positive aspects and challenges/difficulties, 
own and others’ contribution to decision-making), process of agreeing and assigning 
actions, communication of actions to other groups/trial personnel, how future TSC 
meetings could be improved  
Trial funders Funders’ expectations and views of TSCs, process of selecting TSC, examples of TSC 
working well, examples where TSCs haven’t worked well, different models of TSCs, role of 
TSC Chair, role of Patient and Public Involvement (PPI), role of the trial funder, regulatory 
bodies, recommendations re. TSCs   
Sponsors Sponsors’ expectations and views of TSCs, role of sponsor in trial, responsibilities of 
sponsor, relationship between sponsor, TSC and funder, challenges faced by trials, 
qualities of a TSC Chair, decision-making by a TSC, value of TSCs 
 
Data analysis and rigour  
Observational data (meeting recordings and field notes) and interview data were analysed using 
thematic analysis [13]. Preliminary analysis was conducted by the primary researcher (AD) alongside 
data collection, to enable data gathered earlier on to inform subsequent data collection. Through a 
combination of deductive line-by-line coding, based on the research aims, and inductive analysis, an 
initial coding framework was developed using techniques of constant comparison [14]. Members of 
the research team (AS, AL, SM, GS and HC) read and independently coded a sub-set of interview and 
meeting transcripts and met monthly to review data analysis and emerging findings. During the 
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meetings the coding frame was refined into broader categories and higher-level recurring themes, 
and data within themes were scrutinised for disconfirming and confirming perspectives. Finally, a 
narrative summary of the findings which integrated data from the interviews and observations was 
constructed (LS, AD). Triangulation attended to areas of divergence and convergence in the datasets 
and the different perspectives represented. 
The research team represents a range of disciplines and expertise: qualitative health researchers, 
trial methodologists, statisticians and social scientists with backgrounds in psychology, anthropology 
and health services research. Several team members had experience of being on TSCs and were 
known to some of the participants; however, the researcher who collected data had no prior 
relationships with the participants. One of the informants interviewed was a member of the study 
team and is a co-author on this paper, but was not involved in data analysis or interpretation. 
Reflexivity was fostered by the researcher taking detailed field notes on the research process [15] 
and group discussion of the context of knowledge construction at the monthly team meetings [16]. 
Data analysis was managed in NVivo v.10, which helped ensure auditability [17].  
In presenting findings, data have been anonymised to protect confidentiality. ID codes and trial 
number are used to identify quotes from interviews. Observational data from meeting recordings 
and field notes are dated along with trial number.  
Ethical approval: The study was approved by the University of Bristol Faculty of Medicine and 
Dentistry Research Ethics Committee. NHS research governance approval was gained where data 
collection took place on NHS premises or included NHS staff. All interview participants gave written 
informed consent.   
Results 
Eight trials participated, all of which were currently recruiting. Six eligible trials were approached via 
the CTU Network; the CI of one of these refused to participate as the Chair of the TSC did not want 
observers at their first ever meeting, in which building relationships was key. The five other trials 
participated. In addition, of the 32 trial CIs contacted by the funder, five contacted the researchers 
regarding the study. To fulfil our recruitment target of 8 trials, three of these were purposively 
selected to participate.   
We observed and audio-recorded eight TSC meetings and six TMG meetings, totalling 14 hours 45 
minutes. Meetings ranged from 40 minutes to 2 hours in length. We conducted 65 interviews with 
51 individuals, who were either members of the eight trials’ TSCs or TMGs or were other relevant 
informants working in this field (Table 1). No one approached refused to be interviewed. Interviews 
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ranged from 19 minutes to 2 hours 28 minutes (mean 58 minutes). The median number of 
interviews per trial was 10, range 6-11. The ratio of independent to non-independent members of 
TSCs interviewed for each trial ranged from 1:2 to 1:6.  
Insert Table 1 here 
Two main themes with sub-themes emerged: the role of the TSC (quality assurance and patient 
advocacy) and valued attributes of TSC members (experience and independence).  
Roles of the TSC: scientific quality assurance and patient advocacy  
Scientific quality assurance 
The overall role of the TSC was defined in terms of assuring the rigour and quality of trials; for 
example, giving “an independent and knowledgeable view” (05, Sponsor representative, trials 1 & 2) 
of trial progress to guide the trial towards analysis and publication. Participants reported that to 
fulfil this role, the TSC had to be able to objectively critique the trial and hold the trial team to 
account while also providing support and ensuring criticism is constructive. Several interviewees (67, 
Funder representative; 40, Senior trial manager, trial 7; 39, CTU Director, trial 7) used the phrase 
‘critical friend’ to describe this role, while others emphasised the critiquing or challenging 
component of the role; 20, TMG member, trial 4) labelled it ‘tough love’ (Box 2). One TSC Chair (42, 
trial 8) saw the primary and ethically correct role of an independent TSC as that of a ‘critical advisor’ 
who would be willing to be a ‘non-friend’ and give unpalatable advice when a trial faces difficulties.  
Box 2: TSC as ‘critical friend’, provider of ‘tough love’ or ‘critical advisor’: exemplifying quotes  
TSC as ‘critical friend’  The ideal function of the Trial Steering Committee [is to] act as a critical friend to 
the trial, whereby they support the trial to some extent but then they do also ask 
the awkward questions and hold them to account. (50, Senior statistician) 
It was really important to have that external objective view of looking at the data 
independently, but also, them being our critical friends, advising us and supporting 
us through this… they’re there to support and help, they’re not just there to 
chastise. (40, Senior trial manager, trial 7) 
TSC as provider of 
‘tough love’  
[The role of a TSC] is, I think, tough love. (Laughter)… They’ve got to be on your 
side… Because if you’ve got a TSC that’s against you, you might just as well hand 
the money back now. (Laughter)… They’ve got to kind of be in your corner, but I 
think they’ve got to be tough. (20, TMG member, trial 4) 
If I don’t walk out of these meetings feeling like I’ve been given a bit of a kicking 
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then they haven’t done their job properly, that’s what they’re there to do … it’s 
their job to… point out the things that we should be doing better. (23, CI, trial 5)  
TSC as ‘critical advisor’ Interviewer:  When I’ve asked that question of other people, they value the TSC 
being a critical friend. 
42, TSC Chair, trial 8: No, you can’t. It’s not a friend. A friend implies that the 
relationship is a good one and always amicable. I wouldn’t hesitate to be a non-
friend if I thought it was wrong. Critical adviser – better. However, friend does 
imply that, “We’ll sit round the table like friends and we’ll just discuss this and 
what we say will be okay for you.” So criticism; yes, advice; yes. Friendship almost 
comes as a side issue.  
Interviewer: Perhaps the friend bit was them implying that you need to be on their 
side? 
42, TSC Chair: You’re not. 
Interviewer: You’re not? 
42, TSC Chair: No. You’re independent. So the words of wisdom that you give may 
be words they don’t want to hear. Maybe we’re going to say, “Right, this trial 
needs to be shut. It’s not working.” That’s happened three or four times it the last 
couple of years, in other trials groups. It’s not a matter of cutting your losses. It’s a 
question of making sure that it’s the ethically proper thing to do. So I’m very keen 
that meetings are conducted in a friendly environment but we are there as 
advisers and critics. 
 
During observations of TSC meetings, the central role of the Chair in enabling the TSC to fulfil its 
quality assurance role was evident. The TSC Chair of trial 3, for example, seemed to have less control 
of the proceedings compared to other Chairs, taking the CI’s ‘”enthusiastic, optimistic” projections of 
recruitment at face value and skipping items on the agenda to save time, which meant key members 
of the trial team were not given a voice (field notes, TSC meeting trial 3). In contrast, the Chair of 
trial 8 (42, quoted in Box 2) dealt with challenges encountered during the trial by “giving timeframes 
to see improvements” as well as advising about possible solutions (field notes, TSC meeting trial 8).  
However, independent members other than the Chair also played an important role in maintaining 
scientific rigour. The less experienced Chair of trial 7 had a “dream team” with her of two 
experienced TSC independents who provided “guidance and reassurance” to ensure difficult 
decisions regarding the trial’s future were made and implemented successfully (field notes, TSC 
meeting trial 7).  
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In addition, the model of the TSC and its fit with the trial topic also influenced the ability of the TSC 
to fulfil its quality assurance role. One of the TSCs in the study was an ‘umbrella’ TSC which oversaw 
several trials, all in cancer, and reviewed paperwork from 8 trials in the two-hour TSC meeting 
observed. While the discussion of each trial in this meeting was necessarily brief, the reports 
submitted by each trial and circulated to the group in advance were noted to be very detailed, with 
the TSC Chair selecting key elements for discussion. In field notes after the meeting the researcher 
commented on the efficiency of this model where trials are of a similar nature. Those interviewed 
from the TSC suggested that the umbrella model would not work well for complex interventions or 
when the trial itself is complex: 
Where it’s an adaptive trial, lots of different activities it might be better that we’ve got a TSC that 
adapts to the trial, similarly if you got a number of different trial groups involved... That’s one reason 
why you wouldn’t want... to use an umbrella TSC every time. The other is actually is the way that they 
engage: there is a difference in the way they engage at the two hour meeting, looking just at your 
trial... compared to a meeting where they meet for 5 or 20 minutes. (02, Senior trial project lead, trials 
1 & 5) 
 
The same respondent highlighted the benefits of the umbrella model:  
Those guys know their stuff, they know their way around the trials pretty well and the issues come up 
time and time again and they read the papers… There are plusses and minuses of the umbrella 
approach and the standing trial approach, I’d say. I’ve experience of using both and I think they both 
work fairly well. (02, Senior trial project lead, trials 1 & 5) 
 
While the majority of respondents valued the TSC and its contribution to the trial, one CI questioned 
the scientific worth of the TSC. He acknowledged the value of having a body to provide an ‘external 
check’ on trial conduct, but in practice thought a TSC had very little impact: 
It seems, to a large extent, to be a rubber-stamping process ... an external group checking what you're 
doing.  But I'm not sure it makes a huge difference as to the way the trial runs. (29, CI, trial 6) 
The Chair also felt ambivalent about the value and contribution of his TSC when the trial, he 
believed, was running smoothly, and hence the TSC had little to contribute:  
I mean, there wasn’t very much on the agenda really, it’s rather formulaic … because it’s going quite 
well there isn’t a lot to say really. (30, TSC Chair, trial 6) 
In contrast, members of the trial team overseen by this TSC gave specific examples of how the 
independent TSC members had aided the running of the trial:  
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So he (independent member) gave us some great input on improving return rates because he’d worked 
on a trial where they’d used text messages before. (28, Senior statistician, trial 6) 
The trial manager suggested a reason for this difference of opinion regarding the value of the TSC: 
I think it is because I look at things on a day-to-day level, whereas [CI] perhaps looks at things on a 
much more broader basis…I value something like an increase in the questionnaire return rate but he 
(CI) won’t see it as being such a big thing as I do. (26, Trial manager, trial 6) 
These contrasting perspectives highlight that value is judged from a particular viewpoint: different 
members of the trial team may value different forms of input from a TSC. They also suggest that the 
role of the TSC may change depending on how well a trial is doing, from rubber-stamping when 
things are going well to being more critical and directive at other times. 
 
Patient advocacy 
An additional role of TSCs highlighted in the data was that of patient advocacy. The responsibility of 
the committee towards patients participating in trials was emphasised in interviews and observed in 
meetings (“patient value and safety... that’s the guiding thing” (31, TSC Independent Member, trial 
5)). The role of the TSC as ‘patient advocate’ (42, TSC Chair, trial 8; 45, Sponsor representative, trial 
8) was evidenced in phrases such as the patient being the ‘the only reason we’re here’ (01, TSC 
Chair, trials 1 & 2) and the ‘end point in everything’, ‘the top of the pile’ (42, TSC Chair, trial 8):  
During the TSC meeting attended for trial 7, the early stopping of recruitment several months earlier 
was discussed, and the prioritisation of patient well-being was clear: 
37, Independent Statistician, trial 7: That was really the bit I was most interested in… what was going 
to happen with the patients? 
34, CI, trial 7: We did have worries. You remember we set up telephone lines and all this. (Extract from 
TSC meeting, trial 7)   
 
What there was complete agreement about, was concern for participants and the welfare of 
participants in the trial. (39, CTU Director, trial 7) 
The CI described therapeutic alternatives to the trial intervention offered to participants who had 
not yet started therapy, commenting that “the research therapists were brilliant” (34, CI, trial 7, 
quoted from TSC meeting). The team discussed a potential future publication on best practice in 
stopping trials of psychological interventions, given their thorough approach to considering 
participant well-being.  
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As this demonstrates, patient advocacy was not distinct from or in conflict with the scientific quality 
assurance role of the TSC; rather, protecting patient well-being was often perceived as intrinsic to 
assuring trial quality. However, an independent TSC member highlighted that the roles of scientific 
quality assurance and patient advocacy might be prioritised differently by TSC members: 
I think in a philosophical way, [the role of the TSC] is to protect the patient, and then the integrity of 
the trial. I think that should be clear… it puts the interest of the patient first and foremost. As an 
independent, you are making sure that that is observed. (37, Independent statistician, trial 7) 
The participant differentiated ‘patient safety’ from ‘patient well-being’, arguing that the latter is the 
remit of the TSC, while the former is the responsibility of the DMC: 
It’s to protect the patient… not just the safety, I think the wellbeing… because strictly speaking, the 
safety of the patient is the exclusive reserve of the DMC. (37, Independent statistician, trial 7) 
Attributes of TSC members  
For TSC members, particularly Chairs, to fulfil their roles, two attributes emerged as essential: 
relevant experience, and impartiality through their independence. In particular, both were seen to 
enhance the rigour of a trial and enable quality assurance. However, while there was broad 
agreement about the types of experience among TSC members that were of value to a trial, there 
was less consensus about the meaning of independence and how it could be successfully 
implemented in practice. 
Experience 
Experience in three domains was valued in TSC members: experience of running a trial, experience 
of sitting on a TSC or DMC, and experience or expertise in a particular clinical or methodological 
area.  
Participants acknowledged the complexity of trials and valued TSC members’ prior experience of 
involvement in or running a trial. The value of experiential knowledge lay in being able to bring 
practical solutions to problems from their own experience of conducting trials: 
A different view of the world potentially, but also, ‘Well, when we tried that, it did not work, so we 
tried this. Maybe you want to give this a try’ … To suggest solutions from your past experience, your 
past knowledge. (38, TSC Independent Member, trial 7) 
 
Experience of sitting on DMCs or TSCs was also highly regarded by those who were active TSC 
members. A TSC Chair who was relatively inexperienced appreciated the knowledge and capability of 
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the other two independent members on the committee who were experienced in this role, 
especially when the trial went through a challenging period. Without their TSC experience, the Chair 
felt that her role would have been a lot more stressful: 
I probably would have asked permission, probably, to seek advice elsewhere, but (the TSC Independent 
Members) were extremely experienced and couldn’t have been better. (36, TSC Chair, trial 7) 
However, as this kind of advice and support are currently provided informally, some interviewees 
suggested forming a national level advisory board who would advise in complex situations:  
There could be some sort of scientific advisory board, or methodological advisory board… So that 
when you did hit the buffers, you know… there would be a mechanism for saying, “Look we’re in 
difficult circumstances here.”… You could actually have an emergency TSC, of the great and the good 
to descend on the trial. (37, Independent statistician, trial 7) 
The value of experience in specific clinical and methodological areas was also evident in 
observational data. In the observed meeting from trial 8, for example, independent TSC members 
gave advice to the trial team regarding recruitment processes and outcome assessment burden, and 
informed the less experienced Chair about publication policies.    
To ensure relevant experience among TSC members, the Clinical Trials Unit Directors interviewed 
described informal apprenticeship schemes within their units where those with less trial oversight 
experience could gain experience of TSCs and access relevant training. There were different models 
of these apprenticeship schemes, including junior staff taking an observer or non-voting role on a 
TSC or gaining prior experience on a DMC to improve understanding of committees’ respective roles 
and responsibilities:  
The easier way to get experience of this, as trial oversight, is as an observer or a non-voting member 
of a TSC. Then you become a voting member of a TSC. When you’ve got a broad range of experience, 
you then come on a DMC. (39, CTU Director, trial 7) 
When you've been on a DMC and had really difficult decisions to make, you can kind of appreciate 
how much is involved and usually how much racking of brains has gone into it. If you're aware of that 
from the other side sitting on a TSC you think even harder before you overturn the DMC decision. (44, 
Senior statistician, trial 8) 
Independent TSC members were in favour of a more formal and national approach to the concept of 
TSC apprenticeships, which could be incorporated into the continuous professional development of 
research staff.  
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There should be a national bureau or a national register of TSC and DMC members. It should be part of 
my academic obligation say, to take part in four a year, or something… If we organised it on a national 
level, and actually had proper training programmes, on the back of that, so that more junior members 
of staff could get trained up, and kind of get their pilot’s licence - that’s the way to do it. (37, 
Independent statistician, trial 7) 
Establishing a national apprenticeship system was seen to safeguard the quality of future trial 
oversight committees and prevent a dearth of suitably experienced people capable of protecting the 
participants of future trials.  
Independence 
Valued, but difficult to operationalise  
Trial teams valued the independence of the external members of the TSC, associating their distance 
from the design and day-to-day management of the trial with their ability to give impartial advice. In 
particular, the absence of a ‘vested interest’ was seen as essential in enabling the TSC to fulfil its 
patient advocacy role:  
If you have a vested interest in the outcome of the trial as a clinician – trial management, we’ve 
invested in the protocol, we want to deliver it … I would hope that we would always have the same 
approach in thinking about patients first, but I think it’s that assurance really, they don’t have invested 
interest. (12, Senior trial manager, trial 3) 
One CI reflected on how independence provided a valuable check on the emotional and intellectual 
investment of trial team members, which might put them at risk of prioritising recruitment or early 
release of data over patient welfare:  
The independence was key, because at that time, I would have done anything to not have the trial 
stopped. Really, it was correct that it should have been, as per Protocol. Now that things have calmed 
down, you think, “That is how it should have been.” (34, CI, trial 7)  
The independence of TSC members was also valued by sponsors and funders. Sponsors were 
conscious of the wider community’s perception of the quality of a trial. They valued independence 
as it provided a quality kite mark that signalled to outsiders the ‘integrity’ (48, Sponsor 
representative) of the trial: 
For external purposes it's important as well, just how it's perceived by people outside, I think that's 
important…for the rigour and for the integrity of the trial. (48, Sponsor representative) 
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Funders particularly appreciated independent TSC members during challenging times in the life of a 
trial, such as when decisions about continuation of the trial were needed. The independent TSC 
members were considered crucial at such times, given potential biases about trial viability among 
non-independent members: 
Obviously [for] those that have been involved in developing the study … I think it’s quite difficult to 
remain unbiased towards continuation of the study. (49, Funder representative) 
However, perspectives varied as to how ‘independence’ should be defined. Funder representatives 
were aware of the difficulties of implementing independence, particularly in the context of trials 
within in a specific clinical area, in which the same individuals are involved in multiple roles: 
From a tight knit (clinical) community the same people that are either the chief investigators, serving 
on a Trial Steering Committee, serving on our Peer Review Committee, are the same people year after 
year, you know… (49, Funder representative) 
According to some funders’ requirements, independent TSC members should neither be from the 
same institution as any of the applicants or members of the trial team, nor part of an institution 
where participants are being recruited. The narrowness of this definition was criticised due to both 
the difficulty of implementing it and its potential threat to trial conduct. In multi-centre trials 
involving many known experts in the field, independent members were difficult to find; in the words 
of one CI, it “really leaves you kind of short of places to look” (29, CI, trial 6). In one trial, an 
independent member had to resign from the TSC because they changed jobs, disrupting trial 
oversight:  
We got a new independent member because one of the members ... who's actually been the one who's 
made a lot of the good suggestions about what we can do about recruitment and so on... he's moved 
here, and somehow or other that's now a conflict of interest, and I think why? I mean, I still don't know 
the bloke and his expertise hasn’t changed just because he's moved institution, but suddenly he can't 
be an independent member. (29, CI, trial 6) 
Some participants argued that institutional affiliation was less of a threat to independence than 
one’s relationship (e.g. frequent collaborations) with the trial team. While this was acknowledged by 
a Director within a funding body, he still maintained that employment in a separate institution is the 
key factor determining independence: 
People are never a hundred per cent independent in the sense that they’re often known to, and in fact 
they’re nominated by the investigators themselves… but they are nevertheless, independent in a sense 
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they’re not from the same institution and certainly aren’t co-applicants and grant holders on the same 
study. (47, Funder representative) 
Scientific quality of a study was considered at risk when trial teams were required to approach 
‘independent’ members outside the specific clinical area and/or who lacked the detailed knowledge 
that may be helpful to the trial. This could occur when existing experts were judged too close to the 
trial or its team. The requirement of independence thus came into tension with the valued attribute 
of relevant experience: 
It is difficult to describe the [disease x] clinical community as anything other than a web... everyone’s 
interconnected in some way... it’s a small world, so if you want that experience, if you want people 
who know the area, it’s going to be very difficult to get people who aren’t in some way connected. (02, 
Senior trial project lead, trials 1 & 5).  
The [funder] fired me [from a DMC], on the basis that by moving back to [city X], I was now at the 
institution where one of the minor grant holders was... If you insist on that independence, two things 
are going to happen. First of all, almost by definition, you are going to get someone who is out of the 
field. However good they are, they’re not going to know about this specific clinical area. Secondly you 
run the risk of just getting somebody who isn’t very good. (38, TSC Independent member, trial 7)   
‘Going native’ and the appointment of independent TSC members   
The funders interviewed expressed concerns about independent TSC members losing their 
independence over time through their engagement with the trial and the non-independent 
members of the TSC. The term ‘going native’ was used to describe their perception of a lessening of 
impartiality by independent TSC members who became too close to the trial team. This was of 
disquiet to funders, as they saw the TSC as potentially at risk of colluding with the trial team, 
reducing the rigour of a trial: 
We use the phrase “TSCs go native”, where they rather forget that they’re there to provide the 
independent function and…they change into more like the Trial Management Group and see their role 
as, as there to support the researchers. My own view is that that's unhelpful.  (47, Funder 
representative)  
Although there were no obvious examples of this in the observational data, as mentioned above TSC 
Chairs varied in the extent to which they questioned trial team members, with some accepting their 
reports at face value and others exhibiting a more critical approach.  
For independent TSC members, negotiating their role in contributing expertise to a study, while also 
remaining independent, could be challenging:  
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On the one hand, you don’t want to be completely dogmatic about this… you see a car crash 100 yards 
down the road, you don’t sit on your hands and say, “Well I’m duty bound not to, you know, not to 
mention this.” But on the other hand, you do have to be careful, that you don’t roll your sleeves up and 
without really realising it, change your role, from being an independent trials team committee, to 
another organ of the research team. (37, Independent TSC Member, Statistician, trial 7)  
The risk of loss of independence was reported to be a prime motivator for funders seeking control 
over the appointment of external TSC members and the right to appoint new members. However, 
TMG and TSC members expressed concerns about this arrangement, questioning whose interests 
were being served in establishing the TSC, the funder’s or patients’. Independent TSC members and 
CTU directors in particular thought that some funders were increasing their control of governance of 
the TSC while paying inadequate attention to the need for the TSC to be independent from the 
funder. This was described as shifting the focus away from quality assurance on ‘behalf of the 
funder’ towards ‘protecting the purse’ of the funder:  
One of the things, I think… that the [funder] needs to grasp, is that it’s not about protecting their 
purse, because there’s a danger with the way that the [funder] is pushing it: the TSC is seen as 
protecting the funder rather than holding everybody to account and working to ensure that this is 
delivered on behalf of the funder. It’s quite a subtle difference… Some TSC chairs, I think, see 
themselves as closer to the funder than others, and that’s another form of conflict of interest, if you’re 
too close to the funder. That’s not acknowledged at all. (39, CTU Director, trial 7)  
For some respondents, the nature of the relationship between funder and TSC was therefore critical 
to the TSC’s ability to fulfil its patient advocacy role. One independent member of a TSC argued that 
the scientific community, not the funder, should appoint experts to the TSC to uphold the interests 
of patients:  
The TSC is supposed to be an independent organisation, whereas [a Funding Director] now has very 
definitely seen it as first and foremost representing the funder’s interest. Now, I said to him, “Look if 
you just take those letters that you are sending out to all the independents [TSC members] that 
explains their role, just cross out [funder’s name] and put in [pharmaceutical company’s name], and it 
will make very uncomfortable reading.” (38, TSC Independent Member, trial 7) 
Discussion 
This study, the first to explore using qualitative methods the role of TSCs in trials, demonstrates 
tensions and ambiguities in the roles expected of a TSC and the attributes valued of TSC members. 
Scientific quality assurance and patient advocacy were identified as the primary roles of the TSC. The 
quality assurance afforded by the TSC was understood in subtly different ways, reflected in 
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characterisations of the TSC as a supportive ‘critical friend’, a provider of ‘tough love’ or a ‘critical 
advisor’ not afraid to give unpalatable advice. In general, TSCs were highly valued for the role they 
played in steering trial conduct, although perceived value could differ between people involved in 
different capacities in the same trial.  
In fulfilling the role of quality assurance, the attributes of experience and independence were seen 
as critical. Experience enabled TSC members to provide well-informed advice; independence, to 
remain impartial and balance the potential for biases in the trial team. However, we found that the 
requirements of experience and independence could conflict. Operationalising funder definitions of 
independence was difficult, particularly in niche fields of expertise. Here, strict requirements of 
independence were perceived as potentially detrimental to the running of a trial, preventing the 
recruitment of TSC members with relevant experience and expertise. Independence, and therefore 
quality assurance, was also reportedly threatened by TSC members ‘going native’ and losing 
impartiality. This phenomenon motivated funders’ own selection of independent TSC members. 
However, the propriety of this involvement by funders was debated, with some seeing 
independence of the TSC from the funder as critical to the TSC’s ability to fulfil its patient advocacy 
role.  
Findings from this study have clear implications for revisions of the MRC’s guidance and terms of 
reference for TSCs [1, 2]. The tensions we identified point to a lack of clarity in existing guidance in 
the following areas:  
1) The responsibility of the TSC: Is the TSC’s primary responsibility to uphold the interests of 
the funder/sponsor, patient, or both? If the latter, then how should the needs of each be 
balanced? If primary responsibility of the TSC is to the patient, what does this mean for 
involvement of the funder in trial governance? 
2) The meaning of ‘independence’ in the context of a TSC: How should ‘independence’ be 
operationalised, particularly in narrow specialisms in which relatively few people have 
relevant expertise and experience?       
3) The selection of independent TSC members: Related to (1) above, what should the role of 
the funder be in selecting TSC members? Can the interests of patients be upheld if a funder 
is involved in this choice?  
We recommend a revised version of the MRC guidance and terms of reference take into account the 
current ambiguity and lack of clarity in these areas. Clear guidance, standardisation of processes and 
transparent decision -making in these areas are needed. The development of consensus about the 
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appropriate definition of independence, and strategies for operationalising this when establishing a 
TSC, would contribute towards achieving this. The MRC and NIHR guidance clearly indicate a move 
towards the TSC acting “on behalf of the Sponsor and Funder” [4], but debate is needed: should the 
TSC first and foremost represent sponsors’ and funders’ interests? Or should its role primarily be as 
an independent organisation providing overall supervision of the trial? Our study participants gave 
particular weight to the ‘patient advocate’ role of the TSC, even above their recognised role in 
ensuring trial integrity [18], and differentiated between the responsibility of the DMC for patient 
safety and the responsibility of the TSC for patient well-being. However, ensuring patient well-being 
is not currently identified in the MRC Guidelines as one of the key responsibilities of the TSC [2]. 
Updates to TSC terms of reference should consider giving greater prominence to the promotion of 
patient well-being during the oversight process.  
This study has strengths and limitations which should be considered in interpreting the 
transferability of our findings. We utilised multiple ethnographic methods, which allowed an in-
depth exploration of the role of TSCs from several perspectives that would not be possible using 
quantitative or single methods alone. In particular, our observational data demonstrated how 
differences in chairing styles impacted on the ability of a TSC to provide quality assurance, and gave 
insight into how the patient advocacy role of the TSC plays out in a TSC meeting. The eight UK trials 
in our study are not representative of all randomised trials: seven were funded by one UK funder of 
trials and the other by a charity; trials funded through other sources and in other countries may face 
different issues. Furthermore, we selected trials experiencing challenges, and believe this gave us 
added insight into the role of TSCs. However, an interesting area for future research would be to 
compare our findings with the reported roles and value of TSCs in trials which are not undergoing 
such difficulties, as experiences and opinions may differ.  
Our findings support and add to the findings from Harman et al’s expert panel [8]. We found the 
nature of independence to be a key ambiguity in the characterisation of TSCs. The experts in 
Harman’s study, like respondents in this study, raised the question of to whom the TSC was primarily 
responsible, and how this influenced their independence. Ensuring relevant experience and skills 
among TSC members was also raised in both studies, suggesting that capacity building is an area that 
requires attention as the field develops. Participants in our study discussed informal apprenticeship 
schemes designed to ‘train up’ less experienced staff who would become the independent TSC 
members of the future. To ensure the consistent training of potential independent TSC members a 
formal national apprenticeship scheme was suggested. Such a scheme could work if the processes 
and time required for apprentices to observe and reflect on TSC meetings with appropriate mentors 
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are clearly articulated and factored into the funding of trials. The apprenticeship scheme would 
provide experiential ‘on the job’ training of TSC functioning, and not just classroom-based teaching 
of particular skills (e.g. statistics).  
We found that three types of experience among TSC members were valued: experience of running a 
trial, experience of sitting on a TSC or DMC, and experience or expertise in a particular clinical or 
methodological area. All three of these areas of experience were stated as requirements of TSC 
members in a recent survey of registered CTUs [7]. However, this study provides further insight as to 
why trial teams value these types of experience. Where TSC Chairs or independent members lacked 
this experience participants suggested that a national Advisory Board would be useful to advise 
independent TSC members in complex situations, e.g. when facing challenging decisions such as 
stopping a trial.  
Further research is needed to grow the evidence base regarding trial oversight. In particular, the 
relationships between TSC members, the TMG and DMC, and the role of the TSC Chair emerged as 
important in understanding trial oversight in practice; the Damocles project reported similar findings 
in relation to DMCs [6]. Further in-depth investigation in these areas is warranted. In addition, it was 
beyond the scope of this paper to explore the role of PPI representatives in trial oversight and 
conduct, and future research in this area is needed [19].     
Conclusions 
This qualitative study of the TSCs of eight clinical trials facing challenges revealed that independent 
TSC members provide impartial and informed advice to improve scientific rigour, and act as trial 
participants’ advocates to ensure their well-being. However, we found tensions and ambiguities in 
the roles expected of TSCs and the attributes valued of TSC members. In particular, the 
requirements of both independence and experience could conflict, impacting on the quality 
assurance role of the TSC. Although independence of TSC members is valued, operationalising 
funders’ definitions of independence can generate logistical issues. Concerns were raised regarding 
whose interests are served by funders’ criteria of independence; in particular, funders’ selection of 
TSC members was thought to have detrimental ramifications for the TSC’s patient advocacy role. 
These findings should be incorporated in revising guidance and terms of reference for TSCs. 
List of abbreviations 
CI - Chief Investigator 
22 
 
DMC - Data Monitoring Committee 
EME - Efficacy and Mechanism Evaluation Programme 
MRC - Medical Research Council  
NHS - National Health Service 
NIHR - National Institute for Health Research 
TM - Trial Manager 
TMG - Trial Management Group  
TSC - Trial Steering Committee 
Competing Interests 
None 
Authors’ Contributions  
AS, JAL, SM, GS, MS and CG were applicants on the grant that funded this study. AD was the 
Research Associate appointed to the study, conducting the interviews, observations and data 
analysis with the support of AS, JAL, SM, GS and HC. AD produced the first draft of this manuscript. 
LS contributed qualitative expertise, conducted additional analyses and redrafted the manuscript. 
JAL was co-principal investigator with AS, jointly conceived of the study, facilitated recruitment of 
case studies, supported data analysis and contributed to the final draft of the manuscript. SM, GS 
and HC read and commented on components of the data to support data analysis, and commented 
on the final draft of the manuscript. MS and CG facilitated recruitment of case studies and 
commented on manuscript drafts. RM supported data collection and commented on the final draft 
of the manuscript. AS was co-principal investigator with JAL, jointly conceived of the study, advised 
on its conduct, supported data analysis and developed the first draft of the manuscript to final draft. 
All authors read and approved the final manuscript. 
Acknowledgements 
We thank all the participants in this study. We gratefully acknowledge the contribution of the NIHR 
HTA programme in recruiting our case studies. This work was funded by the Medical Research 
Council (MRC) Network of Hubs for Trials Methodology Research (HTMR) (MR/L004933/1- R34) and 
undertaken with the support of the MRC ConDuCT Hub (Collaboration and innovation in Difficult 
or complex randomised Controlled Trials - G0800800).   
 
23 
 
Consent to publish 
Written informed consent was obtained from all participants for publication of their anonymised 
data and individual details in publications and presentations arising from this study. Care has been 
taken care to anonymise participants and trials, such that they will not be identifiable in the paper. 
The consent forms are held by the authors and available for review by the Editor-in-Chief. 
References 
1. Conroy, E., et al., Trial steering committees for randomised controlled trials: updating and 
redeveloping guidance and terms of reference informed by current practice and experience. 
Trials, 2013. 14(1): p. 1-1. 
2. Medical Research Council, Guidelines for good clinical practice in clinical trials. 1998: 
London. 
3. Sydes, M.R., et al., Systematic qualitative review of the literature on data monitoring 
committees for randomized controlled trials. Clin Trials, 2004. 1(1): p. 60-79. 
4. MRC and NIHR, Medical Research Council and National Institute for Health Research Efficacy 
and Mechanism Evaluation Programme Research Governance Guidelines. Southampton. 
5. Damocles Study Group, A proposed charter for clinical trial data monitoring committees: 
helping them to do their job well. The Lancet, 2005. 365(9460): p. 711-722. 
6. Walker, A.E. and S.K. McLeer, Small group processes relevant to data monitoring committees 
in controlled clinical trials: an overview of reviews. Clin Trials, 2004. 1(3): p. 282-96. 
7. Conroy, E.J., et al., Trial Steering Committees in randomised controlled trials: A survey of 
registered clinical trials units to establish current practice and experiences. Clin Trials, 2015. 
12(6): p. 664-76. 
8. Harman, N.L., et al., Exploring the role and function of trial steering committees: results of an 
expert panel meeting. Trials, 2015. 16(1): p. 597. 
9. Seale, C., The quality of qualitative research. 1999: Sage. 
10. McFadden, E., et al., The impact of registration of clinical trials units: the UK experience. Clin 
Trials, 2015. 12(2): p. 166-73. 
11. Kristie Saumure, L.M.G., Data Saturation. , in The SAGE Encyclopedia of Qualitative Research 
Methods. . 2008, SAGE Publications, Inc.: Thousand Oaks, CA. p. 196-197. 
12. Faugier, J. and M. Sargeant, Sampling hard to reach populations. Journal of Advanced 
Nursing, 1997. 26(4): p. 790-797. 
24 
 
13. Braun, V. and V. Clarke, Using thematic analysis in psychology. Qualitative Research in 
Psychology, 2006. 3(2): p. 77-101. 
14. Strauss, A.L. and J. Corbin, Basics of qualitative research: Grounded theory procedures and 
techniques. 1990, Newbury Park, CA: Sage. 
15. Lincoln, Y. and E. Guba, Naturalistic inquiry. 1985, Beverly Hills CA: Sage. 
16. Barry, C.A., et al., Using reflexivity to optimize teamwork in qualitative research. Qual Health 
Res, 1999. 9(1): p. 26-44. 
17. QSR International Pty Ltd, NVivo qualitative data analysis Software, Version 10. 2012. 
18. Baigent, C., et al., Ensuring trial validity by data quality assurance and diversification of 
monitoring methods. Clin Trials, 2008. 5(1): p. 49-55. 
19. Buck, D., et al., From plans to actions in patient and public involvement: qualitative study of 
documented plans and the accounts of researchers and patients sampled from a cohort of 
clinical trials. BMJ Open, 2014. 4(12): p. e006400. 
 
  
25 
 
Table 1: Characteristics of interview participants 
 
Participant 
ID 
Role Gender Trial(s) involved in (subject 
area), where applicable  
01 TSC Chair (Clinician) M 1, 2 (oncology) 
02 Senior trial project lead  M 1, 5 (oncology)  
03 TSC coordinator #1 M 1, 2 (oncology) 
04 TSC coordinator #2 F 1, 2 (oncology) 
05 Sponsor representative  F 1, 2 (oncology) 
06 Sponsor representative  M 1, 2 (oncology) 
07 Trial manager F 1 (oncology)  
08 CI F 2 (oncology) 
09 Trial manager  F 2 (oncology) 
10 Trial manager  M 3 (arthritis) 
11 Senior statistician M 3 (arthritis) 
12 Senior trial manager F 3 (arthritis) 
13 Statistician M 3 (arthritis) 
14 CI M 3 (arthritis) 
15 TSC Chair (Clinician) M 3 (arthritis) 
16 Trial manager F 4 (frailty) 
17 TSC Chair (Methodologist) M 4 (frailty) 
18 CI M 4 (frailty) 
19 TMG Chair  F 4 (frailty) 
20 TMG member  F 4 (frailty) 
21 Trial manager F 5 (oncology) 
22 Statistician F 5 (oncology) 
23 CI M 5 (oncology) 
24 Independent TSC member M 5 (oncology) 
25 Independent TSC member M 5 (oncology) 
26 Trial manager F 6 (urology) 
27 Trial manager F 6 (urology) 
28 Statistician  M 6 (urology) 
29 CI M 6 (urology) 
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30 TSC Chair (Clinician) M 6 (urology) 
31 Independent TSC member M 6 (urology) 
32 TMG member  M 6 (urology) 
33 Trial manager F 7 (psychology) 
34 CI F 7 (psychology) 
35 PPI Representative  M 7 (psychology) 
36 TSC Chair (Clinician) F 7 (psychology) 
37 Independent statistician  M 7 (psychology) 
38 TSC Member M 7 (psychology) 
39 CTU Director F 7 (psychology) 
40 Senior trial manager F 7 (psychology) 
41 Trial manager F 8 (oncology) 
42 Chair (Clinician) M 8 (oncology) 
43 PPI representative  F 8 (oncology) 
44 Senior statistician M 8 (oncology) 
45 Sponsor representative  M 8 (oncology) 
46 CI of other trial/member of TSCs M n/a 
47 Funder representative  M n/a 
48 Sponsor representative  M n/a 
49 Funder representative  F n/a 
50 Senior statistician  F n/a 
51 Funder representative  F n/a  
 
 
 
 
 
